Wegovy for Weight Loss
Wegovy is the weight-loss brand of semaglutide, made by Novo Nordisk. It was the first of the modern GLP-1 medications approved for chronic weight management, in 2021, and it remains one of the two injectable medications BeLite prescribes most. Since December 2025 the same medication is also available as a once-daily pill.
What Wegovy is
Semaglutide mimics GLP-1, a hormone released by the gut after eating. It slows stomach emptying, reduces hunger, and quiets the background “food noise” that makes dieting exhausting. Semaglutide is also the active ingredient in Ozempic and Rybelsus, which are approved for type 2 diabetes at different doses.
What the trials showed
In the 68-week STEP 1 trial, adults without diabetes lost an average of 14.9% of body weight on Wegovy 2.4 mg compared with 2.4% on placebo. About one in three lost 20% or more. In the 2025 head-to-head trial, Zepbound outperformed Wegovy (20.2% versus 13.7%), which is one reason we discuss both options with every patient; see Zepbound vs. Wegovy. Wegovy also has evidence no other weight-loss drug has yet matched: in the SELECT trial it reduced major cardiovascular events by 20% in adults with established heart disease, and the FDA added that indication in 2024. A higher 7.2 mg dose was approved on Mar 19, 2026; we cover it in Wegovy 7.2 mg vs Zepbound.
Who can benefit from Wegovy
Wegovy is indicated for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, and for adolescents 12 and older with obesity. It is a particularly good fit for patients with a history of heart attack, stroke, or coronary disease, given the cardiovascular data. Like all GLP-1 medications, it is not used in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, not combined with other GLP-1 drugs, and not used in pregnancy; the label advises stopping at least two months before trying to conceive.
How it is taken
- One injection under the skin once a week, any day, with or without food.
- Doses step up monthly: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and then the 2.4 mg maintenance dose. Some patients stay at 1.7 mg if that is where they tolerate it best.
- A missed dose can be taken within five days; after that, skip it and continue as scheduled.
Side effects
Nausea, diarrhea, constipation, and vomiting are the usual early side effects and are most noticeable after each dose increase. Serious but uncommon problems include pancreatitis and gallbladder disease. Semaglutide slows stomach emptying, so tell your surgeon or anesthesiologist you take it before any procedure requiring sedation. Preserving muscle during weight loss matters here as with every GLP-1; our muscle-loss guide explains the protein and exercise targets we recommend.
Wegovy at BeLite
BeLite prescribes Wegovy as an injection or, for patients who prefer no needles, as the Wegovy pill. Your provider will help you decide between Wegovy and Zepbound based on your goals, medical history, insurance coverage, and cost. All patients on GLP-1 therapy at BeLite receive nutrition counseling and regular follow-up.
Ready to find out which medication fits you? BeLite Medical Center’s medical providers have been prescribing weight-loss medication in Fairfax since 1995. Schedule online 24/7 at belitecom.simplybook.me or call or text (703) 359-9200. The consultation is free for new patients; the $150 new-patient fee applies only if you enroll.
Disclaimer
This page is general information, not medical advice. Whether any medication is right for you depends on your health history and can only be decided by a licensed medical provider after an evaluation. Prescription medications are prescribed only after an in-person visit at BeLite Medical Center, 3923 Blenheim Blvd, Suite 61A, Fairfax, VA 22030.
Sources (verified September 7, 2026)
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
Medications

Wegovy Pill
The same medication as a once-daily tablet, approved December 2025.

Zepbound
The once-weekly tirzepatide injection that produced more weight loss head-to-head.

Semaglutide
Understand the molecule behind Wegovy, Ozempic, and Rybelsus.































